Bile acid derivatives as ligands of the farnesoid x receptor: Molecular determinants for bile acid binding and receptor modulation

Current Topics in Medicinal Chemistry

Volumn 14, Issue 19, 2014, Pages 2159-2174

  Gioiello, Antimo ^a   Cerra, Bruno ^a   Mostarda, Serena ^a,b   Guercini, Chiara ^b   Pellicciari, Roberto ^a,b   Macchiarulo, Antonio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b TES Pharma   (Italy)

Author keywords

Bile acids; Farnesoid X receptor; Structure activity relationships; Structure property relationships; TGR5

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; BILE ACID; BILE ACID DERIVATIVE; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FEXARAMINE; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HYOCHOLIC ACID; HYODEOXYCHOLIC ACID; INT 767; LITHOCHOLIC ACID; LIVER X RECEPTOR; MFA 1; OBETICHOLIC ACID; OMEGA MURICHOLIC ACID; PREGNANE X RECEPTOR; PX 102; STEROID RECEPTOR COACTIVATOR 1; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG; URSOCHOLIC ACID; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; LIGAND; PROTEIN BINDING;

ARTICLE; CRITICAL MICELLE CONCENTRATION; DOSE RESPONSE; DRUG DESIGN; EC50; HUMAN; HYDROGEN BOND; LIVER PROTECTION; MOLECULAR DOCKING; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925875796     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141112100208     Document Type: Article

References (101)

1. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev., 2009, 89, 147-191.
2. Zhu, Y.; Li, F.; Guo, G.L. Tissue-specific function of farnesoid X receptor in liver and intestine. Pharmacol. Res., 2011, 63, 259-265.
3. Matsubara, T.; Li, F.; Gonzalez, F.J. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol., 2013, 368, 17-29.
4. Gadaleta, R.M.; van Erpecum, K.J.; Oldenburg, B.; Willemsen, E.C.L.; Renooij, W.; Murzilli, S.; Klomp, L.W.J.; Siersema, P.D.; Schipper, M.E.I.; Danese, S.; Penna, G.; Laverny, G.; Adorini, L.; Moschetta, A.; van Mil, S.W.C. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut, 2011, 60, 463-472.
5. Crawley, M.L. Farnesoid x receptor modulators: a patent review. Expert Opin. Ther. Pat., 2010, 20, 1047-1057.
6. Pellicciari, R.; Gioiello, A.; Costantino, G. Potential therapeutic applications of farnesoid x receptor (FXR) modulators. Expert Opin. Ther. Pat., 2006, 16, 333-341.
7. http://www.clinicaltrials.gov/ct2/show/NCT01473524?term=NCT01473524&rank=1. Clinical Trial: NCT01473524.
8. Mudaliar, S.; Henry, R.R.; Sanyal, A.J.; Morrow, L.; Marschall, H.U.; Kipnes, M.; Adorini, L.; Sciacca, C.I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 2013, 145, 574-582.
9. Adorini, L.; Pruzanski, M.; Shapiro, D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today, 2012, 17, 988-997.
10. http://www.clinicaltrials.gov/ct2/show/NCT01265498?term=NCT0 1265498&rank=1. Clinical Trial: NTC01265498
11. Li, Y.; Jadhay, K.; Zhang, Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem. Pharmacol., 2013, 86, 1517-1524.
12. Schaap, F.G.; Trauner, M.; Jansen, P.L.M. Bile acid receptors as target for drug development. Nat. Rev. Gastroenterol. Hepatol., 2014, 11, 55-67.
13. Hollman, D.A.A.; Milona, A.; van Erpecum, K.J.; van Mil, S.W.C. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta, 2012, 1812, 1443–1452.
14. Modica, S.; Gadaleta, R.M.; Moschetta, A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal., 2010, 8, e005.
15. Zhang, Y. Farnesoid X receptor–Acting through bile acids to treat metabolic disorders. Drugs Future, 2010, 35, 635–64.
16. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem., 2012, 4, 1015-1036.
17. Hofmann, A.F.; Hagey, L.R. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci., 2008, 65, 2461-2483.
18. Hofmann, A.F.; Hagey, L.R.; Krasowski, M.D. Bile salts of vertebrates: structural variation and possible evolutionary significance. J. Lipid Res., 2010, 51, 226-246.
19. Hagey, L.R.; Vidal, N.; Hofmann, A.F.; Krasowski, M.D. Evolutionary diversity of bile salts in reptiles and mammals, including analysis of ancient human and extinct giant ground sloth coprolites. BMC Evol. Biol., 2010, 10, 133-156.
20. Gioiello, A.; Venturoni, F.; Tamimi, S.; Custodi, C.; Pellicciari, R.; Macchiarulo, A. Conformational properties of cholic acid, a lead compound at the crossroads of bile acid inspired drug discovery. Med. Chem. Commun., 2014, 5, 750-757.
21. Natalini, B.; Sardella, R.; Gioiello, A.; Ianni, F.; Di Michele, A.; Marinozzi, M. Determination of bile salt critical micellization concentration on the road to drug discovery. J. Pharm. Biomed. Anal., 2014, 87, 62-81.
22. Natalini, B.; Sardella, R.; Camaioni, E.; Gioiello, A.; Pellicciari, R. Correlation between CMC and chromatographic index: simple and effective evaluation of the hydrophobic/hydrophilic balance of bile acids. Anal. Bioanal. Chem., 2007, 388, 1681-1688.
23. Natalini, B.; Sardella, R.; Camaioni, E.; Macchiarulo, A.; Gioiello, A.; Carbone, G.; Pellicciari, R. Derived chromatographic indices as effective tools to study the self-aggregation process of bile acids. J. Pharm. Biomed. Anal., 2009, 50, 613-621.
24. Yeh, H.Z.; Schteingart, C.D.; Hagey, L.R.; Ton-Nu, H.T.; Bolder, U.; Gavrilkina, M.A.; Steinbach, J.H.; Hofmann, A.F. Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid. Hepatology, 1997, 26, 374-385.
25. Hofmann, A.F.; Roda, A. Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem. J. Lipid Res., 1984, 25, 1477-1489.
26. Posa, M. Hydrophobicity and self-association of bile acids with a special emphasis on oxo derivatives of 5 cholanic acid. Curr. Org. Chem., 2012, 16, 1876-1904.
27. Lindenbaum, S.; Rajagopalan, N. Kinetics and thermodynamics of dissolution of lecithin by bile salts. Hepatology, 1984, 4, 124S-128S.
28. Schölmerich, J.; Becher, M.S.; Schmidt, K.; Schubert, R.; Kremer, B.; Feldhaus, S.; Gerok, W. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties-studies on isolated hepatocytes and lipid membrane vesicles. Hepatology, 1984, 4, 661-662.
29. Armstrong, M.J.; Carey, M.C. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol- solubilizing capacities. J. Lipid Res., 1982, 23, 70-80.
30. Roda, A.; Cappelleri, G.; Aldini, R.; Roda, E.; Barbara, L. Quantitative aspects of the interaction of bile acids with human serum albumin. J. Lipid Res., 1982, 23, 490-495.
31. Aldini, R.; Roda, A.; Montagnani, M.; Cerrè, C.; Pellicciari, R.; Roda, E. Relationship between structure and intestinal absorption of bile acids with a steroid or side-chain modification. Steroids, 1996, 61, 590-597.
32. Aldini, R.; Roda, A.; Simoni, P.; Lenzi, P.; Roda, E. Uptake of bile acids by perfused rat liver: evidence of a structure-activity relationship. Hepatology, 1989, 10, 840-845.
33. Sharma, R.; Majer, F.; Peta, V.K.; Wang, J.; Keaveney, R.; Kelleher, D.; Long, A.; Gilmer, J.F. Bile acid toxicity structure–activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg. Med. Chem., 2010, 18, 6886-6895.
34. Roda, A.; Minutello, A.; Angelotti, M.A.; Fini, A. Bile acid structure- activity relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC. J. Lipid Res., 1990, 31, 1433-1443.
35. Sabbatini, P.; Filipponi, P.; Sardella, R.; Natalini, B.; Nuti, R.; Macchiarulo, A.; Pellicciari, R.; Gioiello, A. Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives. Molecules, 2013, 18, 10497-10513.
36. Roda, A.; Grigolo, B.; Aldini, R.; Simoni, P.; Pellicciari, R.; Natalini, B.; Balducci, R. Bile acids with a cyclopropyl-containing side chain. IV. Physicochemical and biological properties of the four diastereoisomers of 3 alpha,7 beta-dihydroxy-22,23-methylene-5 beta-cholan-24-oic acid. J. Lipid Res., 1987, 28, 1384-1397.
37. Pellicciari, R.; Natalini, B.; Cecchetti, S.; Porter, B.; Roda, A.; Brunella, G.; Balducci, R. Bile acids with a cyclopropyl-containing side chain. 3. Separation, identification, and properties of all four stereoisomers of 3-alpha,7-beta-dihydroxy-22,23-methylene-5- beta-cholan-24-oic acid. J. Med. Chem., 1988, 31, 730-736.
38. Pellicciari, R.; Cecchetti, S.; Natalini, B.; Roda, A.; Grigolo, B.; Fini, A. Bile acids with cyclopropane-containing side chain. 2. Synthesis and properties of 3-alpha,7-beta-dihydroxy-22,23- methylene-5-beta-cholan-24-oic acid (2-sulfoethyl)amide. J. Med. Chem., 1985, 28, 239-242.
39. Pellicciari, R.; Cecchetti, S.; Natalini, B.; Roda, A.; Grigolo, B.; Fini, A. Bile acids with a cyclopropyl-containing side chain. 1. Preparation and properties of 3-alpha,7-beta-dihydroxy-22,23- methylene-5-beta-cholan-24-oic acid. J. Med. Chem., 1984, 27, 746-749.
40. Roda, A.; Pellicciari, R.; Gioiello, A.; Neri, F.; Camborata, C.; Passeri, D.; De Franco, F.; Spinozzi, S.; Colliva, C.; Adorini, L.; Montagnani, M.; Aldini, R. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat. J. Pharmacol. Exp. Ther., 2014, 350, 56-68.
41. Hofmann, A.F. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology, 2009, 49, 1403–1418.
42. Vlahcevic, Z.R.H.; Heuman, D.M.; Hylemon, P.B. Physiology and pathophysiology of enterohepatic circulation of bile acids. In: Hepatology: a textbook of liver disease; Zakim, F.; Boyer, T.; EDs.; W.B. Sanders Co: Philadelphia, 1996, pp. 376–471.
43. Heubi, J.E.; Setchell, K.D.R.; Bove, K.E. Inborn errors in bile acid metabolism. Semin. Liver Dis., 2007, 27, 289-294.
44. Gioiello, A.; Cerra, B.; Zang, W.; Vallerini, G.P.; Costantino, G.; De Franco, F.; Passeri, D.; Pellicciari, R.; Setchell, K.D.R. Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3-hydroxy-5-C27-steroid oxidoreductase de ciency. J. Steroid Biochem Mol. Biol., 2014, 144, 348-360.
45. Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov., 2008, 7, 678-693.
46. De Aguiar Vallim, T.Q.; Tarling, E.J.; Edwards, P.A. Pleiotropic roles of bile acids in metabolism. Cell Metab., 2013, 17, 657-669.
47. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lusting, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284, 1362-1365.
48. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, T.G.; Kliewer, S.A.; Stimmel, J.B.; Wilson, T.M.; Zavacki, A.M.; Moore, D.D.; Lehmann, J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284, 1365-1368.
49. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell., 1999, 3, 543-553.
50. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell., 1995, 81, 687-693.
51. Zavacki, A.M.; Lehmann, J.M.; Seol, W.; Willson, T.M.; Kliewer, S.A.; Moore, D.D. Activation of the orphan receptor RIP14 by retinoids. Proc. Natl. Acad. Sci. USA, 1997, 94, 7909-7914.
52. Sinal, C.J.; Tohkin, M.; Miyata, M.; Ward, J.M.; Lambert, G.; Gonzalez, F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell., 2000, 102, 731-744.
53. Inagaki, T.; Choi, M.; Moschetta, A.; Peng, L.; Cummins, C.L.; McDonald, J.G. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metabolism, 2005, 2, 217-225.
54. Ma, K.; Saha, P.K.; Chan, L.; Moore, D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest., 2006, 116, 1102-1109.
55. Watanabe, M.; Houten, S.M.; Wang, L.; Moschetta, A.; Mangelsdorf, D.J.; Heyman, R.A.; Moore, D.D.; Auwerx, J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest., 2004, 113, 1408-1418.
56. Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA, 2006, 103, 1006–1011.
57. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.C.; Gonzalez, F.J.; Kuipers, F.; Staels, B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem., 2006, 281, 11039–11049.
58. Lu, T.T.; Makishima, M.; Repa, J.J.; Schoonjans, K.; Kerr, T.A.; Auwerx, J.; Mangelsdorf, D. J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell., 2000, 6, 507-515.
59. Grober, J.; Zaghini, I.; Fujii, H.; Jones, S.A.; Kliewer, S.A.; Willson, T.M.; Ono, T.; Besnard, P. Identification of a bile acidresponsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid x receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem., 1999, 274, 29749-29754.
60. Denson, L.A.; Sturm, E.; Echevarria, W.; Zimmerman, T.L.; Makishima, M.; Mangelsdorf, D.J. The orphan nuclear receptor, SHP, mediates bile acid-induced inhibition of the rat bile acid transporter, NTCP. Gastroenterology, 2001, 121, 140-147.
61. Ananthanarayanan, M.; Balasubramanianan, N.; Makishima, M.; Mangelsdorf, D.J.; Suchy, F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem., 2001, 276, 28857-28865.
62. Wang, Y.D.; Chen, W.D.; Wang, M.; Yu, D.; Forman, B.M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology, 2008, 48, 1632–1643.
63. Li, J.; Wilson, A.; Kuruba, R.; Zhang, Q.; Gao, X.; He, F.; Zhang, L.M.; Pitt, B.R.; Xie, W.; Li, S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res., 2008, 77, 169–177.
64. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Ricciardi, L.; Orlandi, S.; Pruzanski, M.; Morelli, A.; Pellicciari, R. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther., 2005, 314, 584–595.
65. Stojancevic, M.; Stankov, K.; Mikov, M. The impact of FXR activation on intestinal permeability in inflammatory bowel disease. Can. J. Gastroenterol., 2012, 26, 631-637.
66. Xie, W.; Radominska-Pandya, A.; Shi, Y.; Simon, C.M.; Nelson, M.C.; Ong, E.S.; Wasman, D.J.; Evans, R.M. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 3375-3380.
67. Staudinger, J.L.; Goodwin, B., Jones, S.A.; Hawkins-Brown, D.; MacKenzie, K.I.; LaTour, A.; Liu, Y.; Klaassen, C.D.; Brown, K.K.; Reinhard, J.; Willson, T.M.; Koller, B.H.; Kliewer, S.A. The nuclear receptor PXR is a lithocholic acid sensor that protect against liver toxicity. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 3369-3374.
68. Makishima, M.; Lu, T.T.; Xie, W.; Whitfield, G.K.; Domoto, H.; Evans, R.M.; Haussler, M.R.; Mangelsdorf, D.J. Vitamin D receptor as an intestinal bile acid sensor. Science, 2002, 296, 1313-1316.
69. Goodwin, B.; Gauthier, K.C.; Umetani, M.; Watson, M.A.; Lochansky, M.I.; Collins, J.L.; Leitersdorf, E.; Mangelsdorf, D.J.; Kliewer, S.A.; Repa, J.J. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 223-228.
70. Raufman, J.-P.; Zimniak, P.; Bartoszko-Malik, A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach. Am. J. Physiol., 1998, 274, G997-G1004.
71. Raufman, J.-P.; Chen, Y.; Zimniak, P.; Cheng, K. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonist. Pharmacology, 2002, 65, 215-221.
72. Chen, X.; Yang, D.; Shen, W.; Dong, H.F.; Wang, J.M.; Oppenheim, J.J.; Howard, O.M.Z. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm. Res., 2000, 49, 744-755.
73. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 2002, 298, 714-719.
74. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujino, M. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem., 2003, 278, 9435-9440.
75. Giorgio, C.; Hassan-Mohamed, I.; Flammini, L.; Barocelli, E.; Incerti, M.; Lodola, A.; Tognolini, M. Lithocholic acid is an Ephephrin ligand interfering with Eph-kinase activation. PLoS One, 2011, 6, e18128.
76. Russo, S.; Incerti, M.; Tognolini, M.; Castelli, R.; Pala, D.; Hassan- Mohamed, I.; Giorgio, C.; De Franco, F.; Gioiello, A.; Vicini, P.; Barocelli, E.; Rivara, S.; Mor, M.; Lodola, A. Synthesis and structure- activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules, 2013, 18, 13043-13060.
77. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P.R.; Morelli, A.; Parks, D.J.; Willson, T.M. 6alphaethyl- chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45, 3569-3572.
78. Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B.M.; Entrena, A.; Willson, T.M.; Fiorucci, S.; Clerici, C.; Gioiello, A. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem., 2004, 47, 4559-4569.
79. Pellicciari, R.; Sato, H.; Gioiello, A.; Costantino, G.; Macchiarlo, A.; Sadeghpour, B.M.; Giorgi, G.; Schoonjans, K.; Auwerx, J. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem., 2007, 50, 4265-4268.
80. Fujino, T.; Une, M.; Imanaka, T.; Inoue, K.; Nishimaki-Mogami, T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. J. Lipid Res., 2004, 45, 132-138.
81. Pellicciari, R.; Gioiello, A.; Sabbatini, P.; Venturoni, F.; Nuti, R.; Colliva, C.; Rizzo, G.; Adorini, L.; Pruzansky, M.; Roda, A.; Macchiarulo, A. Avicholic acid: a lead compound from birds on the route to potent TGR5 modulators. ACS Med. Chem. Lett., 2012, 3, 273-277.
82. Pellicciari, R.; Gioiello, A.; Macchiarulo, A.; Thomas, C.; Rosatelli, E.; Natalini, B.; Sardella, R.; Pruzanski, M.; Roda, A.; Pastorini, E.; Schoonjans, K.; Auwerx, J. Discovery of 6-ethyl-23(S)- methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem., 2009, 52, 7958-7961.
83. Sato, H.; Macchiarulo, A.; Thomas, C.; Gioiello, A.; Une, M.; Hofmann, A.F.; Saladin, R.; Schoonjans, K.; Pellicciari, R.; Auwerx, J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem., 2008, 51, 1831-1841.
84. Macchiarulo, A.; Gioiello, A.; Thomas, C.; Massarotti, A.; Nuti, R.; Rosatelli, E.; Sabbatini, P.; Schoonjans, K.; Auwerx, J.; Pellicciari, R. Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5. J. Chem. Inf. Model, 2008, 48, 1792-1801.
85. Rizzo, G.; Passeri, D.; De Franco, F.; Ciaccioli, G.; Donadio, L.; Rizzo, G.; Orlandi, S.; Sadeghpour, B.; Wang, X.X.; Jiang, T.; Levi, M.; Pruzanski, M.; Adorini, L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol., 2010, 78, 617-630.
86. D’Amore, C.; Di Leva, F.S.; Sepe, V.; Renga, B.; Del Gaudio, C.; D’Auria, M.V.; Zampella, A.; Fiorucci, S.; Limongelli, V. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J. Med. Chem., 2014, 57, 937-954.
87. Fukuchi, J.; Song, C.; Dai, Q.; Hiipakka, R.A.; Liao, S. 5-Cholane activators of the farnesol X receptor. J. Steroid. Biochem. Mol. Biol., 2005, 94, 311-318.
88. Pellicciari, R.; Gioiello, A.; Costantino, G.; Sadeghpour, B.M.; Rizzo, G.; Meyer, U.; Parks, D.J.; Entrena-Guadix, A.; Fiorucci, S. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J. Med. Chem., 2006, 49, 4208-4215.
89. Gioiello, A.; Macchiarulo, A.; Carotti, A.; Filipponi, P.; Costantino, G.; Rizzo, G.; Adorini, L.; Pellicciari, R. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)- 3,7-dihydroxy-6-ethyl-24-nor-5-cholan-23-amine. Bioorg. Med. Chem., 2011, 19, 2650-2658.
90. Iguchi, Y.; Kihira, K.; Nishimaki-Mogami, T.; Une, M. Structureactivity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids, 2010, 75, 95-100.
91. Mi, L.Z.; Devarakonda, S.; Harp, J.M.; Han, Q.; Pellicciari, R.; Willson, T.M.; Khorasanizadeh, S.; Rastinejad, F. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell., 2003, 11, 1093-1100.
92. Costantino, G.; Macchiarulo, A.; Entrena-Guadix, A.; Camaioni, E.; Pellicciari, R. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). Bioorg. Med. Chem. Lett., 2003, 13, 1865-1868.
93. Bledsoe, R.K.; Montana, V.G.; Stanley, T.B.; Delves, C.J.; Apolito, C.J.; McKee, D.D.; Consler, T.G.; Parks, D.J.; Stewart, E.L.; Willson, T.M.; Lambert, M.H.; Moore, J.T.; Pearce, K.H.; Xu, H.E. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell, 2002, 110, 93-105.
94. Brzozowski, A.M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in the estrogen receptor. Nature, 1997, 389, 753-758.
95. Sack, J.S.; Kish, K.F.; Wang, C.; Attar, R.M.; Kiefer, S.E.; An, Y.; Wu, G.Y.; Scheffler, J.E.; Salvati, M.E.; Krystek, S.R.; Weinmann, R.; Einspahr, H.M. Crystallographic structures of the ligandbinding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A, 2001, 98, 4904-4909.
96. Shiau, A.K.; Barstad, D.; Loria, P.M.; Cheng, L.; Kushner, P.J.; Agard, D.A.; Greene, G.L. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell., 1998, 95, 927-937.
97. Williams, S.P.; Sigler, P.B. Atomic structure of progesterone complexed with its receptor. Nature, 1998, 393, 392-396.
98. Nishimaki-Mogami, T.; Kawahara, Y.; Tamehiro, N.; Yoshida, T.; Inoue, K.; Ohno, Y.; Nagao, T.; Une, M. 5Alpha-bile alcohols function as farnesoid X receptor antagonists. Biochem. Biophys. Res. Commun., 2006, 339, 386-391.
99. Katona, B. W.; Cummins, C. L.; Ferguson, A. D.; Li, T.; Schmidt, D. R.; Mangelsdorf, D. J.; Covey, D. F. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids. J. Med. Chem., 2007, 50, 6048-6058.
100. Macchiarulo, A.; Nuti, R.; Eren, G.; Pellicciari, R. Charting the chemical space of target sites: insights into the binding models of amine and amidine groups. J. Chem. Inf. Model, 2009, 49, 900-912.
101. Yang, L.; Broderick, D.; Jiang, Y.; Hsu, V.; Maier, C. S. Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: Insights into the antagonism of the hypolipidemic agent Z-guggulsterone. Biochim. Biophys. Acta, 2014, 1844, 1684–1693.